Latest Venture capital management company biotechnology articles and news on biotech industry leaders, emerging biotech companies in Spain

OneChain Immunotherapeutics achieves FDA Orphan Drug designation for OC-1

by Parc Científic de Barcelona

7 months ago
OneChain Immunotherapeutics, acute lymphoblastic leukemia (ALL), OC-1

Spanish biotech OneChain Immunotherapeutics (OCI), has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA)to OC-1, a CAR T therapy against for the treatment of acute lymp...

Asabys’ portfolio company Agomab Raises $100 Million Series C from Fidelity, EQT Life Sciences, Canaan and KKR

by Asabys Partners

7 months ago
AGMB-129, Fibrostenosing Crohn’s Disease (FSCD), Agomab, Idiopathic Pulmonary Fibrosis, Asabys

Agomab Therapeutics NV ('Agomab') today announced the closing of a $100 million Series C round of financing to support the Phase 2a clinical trial evaluating Agomab's lead drug candidate, AGMB-129, a ...

Nace el primer fondo dedicado a la Salud Digital en España

by CRB Inverbío SA SGECR

6 months ago
CRB Inverbío

CRB Inverbío, fundada, entre otros, por Enrique Castellón Leal y presidida por Joaquín Velasco, amplía su portafolio con un tercer fondo de capital riesgo dedicado a proyectos de Salud Digital tan...

Swanlaab launches Agri-Food Tech Fund, the first major venture fund specialized in innovation in the agri-food sector

by Asebio

6 months ago
Swanlaab AgriFood Tech, agri-food sector

Spain's first Agri-Food Tech-focused Venture Capital fund kicks off with an initial capital of over 40 million, with a maximum target of 80 million, to invest in technological innovation as a solution...

MONDRAGON y Bexen Medical invierten en Cocoon Bioscience

by Cocoon Bioscience

6 months ago
Bexen Medical, Columbus Venture Partners, Cleon Capital, North South Ventures, Sangha Capital, MONDRAGON

Cocoon Bioscience ha levantado €2 millones en una ronda de inversión liderada por MONDRAGON, Bexen Medical, Columbus Venture Partners y Cleon Capital, y que ha incluido a su vez a Viscofan, la esta...

Kynexis, a biotechnology company focused on precision therapeutics for brain diseases, closes a €57 million in Series A financing led by Forbion, with participation from Ysios Capital and Sunstone Life Science Ventures

by Ysios Capital

6 months ago
Ysios Capital, Kynexis, KYN5356, brain diseases, KAT-II

This capital increase will allow Kynexis to advance the development of KYN5356, an innovative quinurenine aminotransferase II (KAT-II) enzyme inhibitor, for the treatment of cognitive impairment assoc...

Manina Medtech, Vall d’Hebron spin-off, closes an investment round to develop a medical device to increase the success of In Vitro Fertilization

by Vall d’Hebron

6 months ago
vitro fertilization (IVF), SEEDCHRONY, Manina Medtech

After carrying out a first feasibility trial in collaboration with the Assisted Reproduction Section of the Vall d'Hebron Hospital, Manina Medtech is moving towards a pilot trial in IVF patients.

Nanological cierra una ronda de financiación de €600.000 liderada por Clave Capital

by Nanological

5 months ago
Clave Capital, Nanological

Este capital permite acelerar el desarrollo de su línea para el diagnóstico de sepsis en fases iniciales. La sepsis es una disfunción orgánica causada por una respuesta inmunitaria desregulada ant...

Ocean Ecostructures capta 1,6M€ para regenerar la biodiversidad marina

by Ship2B Ventures

5 months ago
Ocean Ecostructures, Ship2B Ventures

Fundada en Barcelona en 2020, OCEAN ECOSTRUCTURES ha desarrollado una tecnología propia de última generación (Bio Boosting System) que revierte el impacto negativo que históricamente han tenido la...

MiMARK Diagnostics, S.L. successfully Closes First Seed Round with €4.22 Million to Impact on Gynecological Diagnostics

by MiMARK Diagnostics

5 months ago
Canterbury Scientific, MiMARK Diagnostics, EIC Accelerator, Clave Capital, Nara Capital, Namarel Ventures, WA4STEAM, CDTI Innvierte, Inveready

MiMARK Diagnostics, S.L. a pioneering femtech spin-off from the Vall d'Hebron Research Institute (VHIR), has successfully raised €4.22 million as seed round stage. The substantial investment will dr...

ALLOX, a new Centre for Genomic Regulation spin-off, is launched with the support of Asabys

by Asabys Partners

5 months ago
ALLOX, Sabadell Asabys II, Asabys Partners, CRG, allosteric sites

ALLOX, a techbio company developing a proprietary technology to design new drugs targeting allosteric sites within oncology and other diseases, announces its incorporation today, as well as the succes...

Investigadores del grupo de enfermedades neurodegenerativas del HUMV-IDIVAL participan en un estudio europeo que define los estadios preclínicos de la ataxia dominante tipo SCA3 a partir de biomarcadores

by Instituto de Investigación Marqués de Valdecilla

5 months ago
ataxia cerebelosa autosómico dominante, SCA3, ataxina 3 (ATXN3)

Investigadores del grupo de enfermedades neurodegenerativas de IDIVAL y del CSUR de ataxias y paraplejías hereditarias del HUMV participan en un estudio multicéntrico europeo diseñado para la ident...